Background: We aimed to evaluate the efficacy and safety of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) plus TPC chemotherapy (NAB-paclitaxel, cisplatin or lobaplatin, and capecitabine) in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) who failed to PD-1 inhibitor-containing regimens.
Methods: In this single-arm, open-label, phase 2 study, RM-NPC patients who failed to at least one line of systemic chemotherapy and anti-PD-1 immunotherapy were enrolled and received cadonilimab plus TPC chemotherapy every 3 weeks for up to 6 cycles, followed by cadonilimab plus capecitabine every 3 weeks for a maximum of 2 years. The primary endpoint was the objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response (DoR), and safety.
Results: Twenty-five patients were enrolled (84% male; median age 44 years (range, 24-60)), with a median follow-up of 10.2 months. The ORR was 68%, with 3 complete responses, 14 partial responses, and 6 stable diseases. The median DoR was 9.1 months (95% CI, 3.8-14.5 months). The median PFS was 10.6 months (95% CI, 5.2-16.0 months). The 12-month OS was 75.6%. Treatment was well tolerated. Grade 3 or 4 treatment-related adverse events occurred in 12 (48%) patients. Fourteen patients (56%) experienced potentially immune-related adverse events (irAEs). One patient experienced a grade 3 immune-related rash and another patient had grade 3 immune-related lipase increased. No treatment-related death occurred.
Conclusions: Cadonilimab in combination with TPC chemotherapy demonstrated promising antitumoral efficacy and manageable toxicities in patients with RM-NPC who failed frontline immunotherapy. Further trials are warranted to confirm and expand these findings.
Trial Registration: This trial was registered at chictr.org.cn (ChiCTR2200067057).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1186/s12916-025-03985-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phytochemical analysis, antioxidant activity, and cytotoxic effects of Caulerpa lentillifera extracts inducing cell apoptosis and sub-G/G0-G1 cell cycle arrest in KON oral cancer cells.
BMC Complement Med Ther
March 2025
Division of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Burapha University, Chonburi, Thailand.
Background: Marine algae have excellent phytoconstituents with notable biological activity and bioactive therapeutic benefits, but the anti-oral cancer activity of Caulerpa lentillifera (C. lentillifera) has not been widely studied. This study aimed to explore the anti-cancer properties of C.
View Article and Find Full Text PDFEfficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.
BMC Med
March 2025
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Department of Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Background: We aimed to evaluate the efficacy and safety of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) plus TPC chemotherapy (NAB-paclitaxel, cisplatin or lobaplatin, and capecitabine) in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) who failed to PD-1 inhibitor-containing regimens.
Methods: In this single-arm, open-label, phase 2 study, RM-NPC patients who failed to at least one line of systemic chemotherapy and anti-PD-1 immunotherapy were enrolled and received cadonilimab plus TPC chemotherapy every 3 weeks for up to 6 cycles, followed by cadonilimab plus capecitabine every 3 weeks for a maximum of 2 years. The primary endpoint was the objective response rate (ORR).
Wearable photobiomodulation halts thyroid cancer growth by leveraging thyroid photosensitivity.
Bioeng Transl Med
March 2025
Department of Endocrinology Nanjing Drum Tower Hospital, School of Life Science and Technology, China Pharmaceutical University Nanjing China.
With papillary thyroid carcinoma (PTC) rates rising significantly, concerns about conventional treatments like thyroidectomy and radiotherapy highlight the need for non-invasive options. Our study explores photobiomodulation therapy (PBMT), which uses specific light wavelengths to evoke cellular responses in PTC treatment. Our research utilized a custom-designed optical system to investigate PBMT, finding that blue light at a wavelength of 465 nm can safely and effectively inhibit the proliferation of the TPC-1 PTC cell line by inducing cell cycle arrest.
View Article and Find Full Text PDFThe Impact of Video-assisted Thoracoscopic Versus Percutaneous Tunneled Pleural Catheter Techniques on Pleurodesis Outcomes: A Retrospective, Single-center Study.
J Bronchology Interv Pulmonol
April 2025
Department of Medicine, Section of Pulmonary, Critical Care Medicine.
Background: Tunneled pleural catheters (TPCs) generate an inflammatory reaction, which, along with frequent drainage, aids in achieving pleurodesis enabling removal in 30% to 50% of patients. However, it is unknown whether the technique of TPC placement influences pleurodesis outcomes.
Methods: This is a retrospective, single-center study of patients who underwent TPC placement from 2010 through 2018.
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.
Ann Oncol
February 2025
Department of Medicine, Division of Hematology/Oncology, University of Washington, Fred Hutchinson Cancer Center, Seattle, USA.
Background: Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, demonstrated efficacy and manageable toxicity in the phase II TROPHY-U-01 study in pretreated advanced urothelial carcinoma (aUC). We report the results from final analysis of the global open-label randomized phase III TROPiCS-04 study (NCT04527991) in pretreated aUC.
Patients And Methods: Patients with aUC whose disease had progressed on prior platinum-based chemotherapy and checkpoint inhibitor therapy were randomized 1 : 1 to receive SG or treatment of physician's choice (TPC; paclitaxel, docetaxel, or vinflunine).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!